Skip to content
Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo Cartherics – The future of cancer treatment : off-the-shelf cellular immunotherapy for cancer. Logo
  • Home
  • Our Vision
  • Our Team
    • Board Members & Key Executives
    • Key Consultants
    • Scientific Advisory Board
    • Scientists
    • Past students
    • Office / Administration
    • Clinical & Regulatory Staff and Consultants
  • Cartherics News
  • Publications and Presentations
  • Our Technologies
    • CAR-T Technology
    • Cancer and the immune system
    • Our Lab
  • Join us
    • Investors
    • New Positions/ Recruitment
    • Education Opportunities
  • Contact Us

Publications and Presentations

Home > Publications and Presentations
Publications and Presentationscarth_admin2020-10-20T00:39:29+00:00

Targeting human ovarian cancer with immune cells derived from the patient or from homozygous hla haplotype ips cells

Chimeric antigen receptors (CARs) have been used for efficient destruction of B cell tumors but have been relatively ineffective as therapy for solid tumors. Ovarian cancer is a difficult cancer to treat, with five-year survival rates commonly around 25% of patients at diagnosis.
Abstract (pdf)

Off-the-shelf iPSC derived CAR-NK immunotherapy for solid tumors

Principal Scientist Dr Nicholas Boyd

The clinical impact of Chimeric Antigen Receptor T cell (CAR-T) technologies on hematological malignancies have revolutionized cancer treatment. 

However, current autologous CAR-T therapies face major roadblocks for mass adoption. 

Published (pdf)
Abstract (pdf)

iScience Review – Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells

Despite progress in developing cell therapies, such as T cell or stemcell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application.

Given the fact that a host’s immune system may reject allogeneic transplanted cells, methods have been developed to genetically modify patients’primary cells.

Download (pdf)

Presentation: Cartherics on the Mesa

In October 2019 Cartherics attended the prestigious Cell & Gene Meeting on the Mesa https://www.meetingonthemesa.com/ in Carlsbad, California.

Cartherics Chief Scientific Officer, Richard Boyd, presented details to delegates of Cartherics’ pre-clinical in vitro and animal model research, cell manufacture for clinical trials, and corporate game plan.

Download (pdf)

Sign up for investor news and Cartherics updates

Latest News

Cartherics Celebrates Academic Achievements
General The Pipeline

Cartherics Celebrates Academic Achievements

December 21, 2020
Doctoral students achieve key milestones  By Leigh Dayton 21 December 2020 As a rough year for all comes to an...
The world desperately needs science and technology to provide the path forward for all of us living creatures

The world desperately needs science and technology to provide the path forward for all of us living creatures

December 17, 2020
Writing today Research Australia’s INSPIRE magazine, Cartherics CEO Alan Trounson highlights the role GSK plays in supporting medical research December...
The Power Of  The Pivot – Lessons from the biotech frontline
General In the media The Pipeline

The Power Of The Pivot – Lessons from the biotech frontline

November 19, 2020
Back People Not Projects By Ian Nisbet* https://www.innovationaus.com/the-pivot-lessons-from-the-biotech-frontline/ “If plan A doesn't work, the alphabet has 25 more letters -...

Latest video

https://youtu.be/WprTZ_scgNw

Contact Us

Address
Level 7 Monash Health Translation Precinct
Hudson Institute for Medical Research
27-31 Wright Street
Clayton 3168 VIC Australia

Contact
+61 3 8572 2500
info@cartherics.com

Links

  • Home
  • Our Vision
  • Contact Us
  • Privacy Policy

Connect with us

Copyright ©     |   Cartherics Pty ltd